Bibliotecas PUC-SP - Busca Integrada

Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer

Por Peter Paul Yu, Omar Eton, Louis P. Garrison
Publicado no Journal for ImmunoTherapy of Cancer (2019-09-01)

Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting?

Por Bernarda Zamora, Louis P. Garrison, Aig Unuigbe, Adrian Towse
Publicado no Cost Effectiveness and Resource Allocation (2021-03-01)

Why is the market design for innovative pharmaceuticals not well understood?

Por Francisco Olivenca, Jose Diaz, Sreeram V Ramagopalan, Louis P Garrison Jr
Publicado no Journal of Comparative Effectiveness Research (2024-09-01)

Is the price right? Paying for value today to get more value tomorrow

Por Sreeram V. Ramagopalan, Jose Diaz, Grace Mitchell, Louis P. Garrison, Peter Kolchinsky
Publicado no BMC Medicine (2024-01-01)

The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.

Por Bruce Wang, Joshua A Roth, Hiep Nguyen, Eugene Felber, Wes Furnback, Louis P Garrison
Publicado no PLoS ONE (2015-01-01)

A prospective model of the potential clinical and economic impact of cervical cancer screening supported by a mobile phone app.

Por Fredrick Chite Asirwa, Brian W Bresnahan, Faith Yego, Dana Duncan, James K Karichu, Louis P Garrison
Publicado no PLoS ONE (2025-01-01)

Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy Implications

Por András Incze, András Incze, Zoltán Kaló, Zoltán Kaló, Jaime Espín, Éva Kiss, Sophia Kessabi, Louis P. Garrison
Publicado no Frontiers in Pharmacology (2022-04-01)

Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?

Por Maarten J. Postma, Declan Noone, Mark H. Rozenbaum, John A. Carter, Marc F. Botteman, Elisabeth Fenwick, Louis P. Garrison
Publicado no Orphanet Journal of Rare Diseases (2022-04-01)

Potential cost-effectiveness of universal access to modern contraceptives in Uganda.

Por Joseph B Babigumira, Andy Stergachis, David L Veenstra, Jacqueline S Gardner, Joseph Ngonzi, Peter Mukasa-Kivunike, Louis P Garrison
Publicado no PLoS ONE (2012-01-01)

Cost-effectiveness of cervical cancer screening and preventative cryotherapy at an HIV treatment clinic in Kenya

Por Marita R. Zimmermann, Elisabeth Vodicka, Joseph B. Babigumira, Timothy Okech, Nelly Mugo, Samah Sakr, Louis P. Garrison, Michael H. Chung
Publicado no Cost Effectiveness and Resource Allocation (2017-07-01)

Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda.

Por Joseph B Babigumira, Barbara Castelnuovo, Andy Stergachis, Agnes Kiragga, Petra Shaefer, Mohammed Lamorde, Andrew Kambugu, Alice Muwanga, Louis P Garrison
Publicado no PLoS ONE (2011-03-01)

Assessing the potential cost-effectiveness of centralised versus point-of-care testing for hepatitis C virus in Pakistan: a model-based comparison

Por Louis P Garrison, Joseph B Babigumira, Samantha Clark, Saeed S Hamid, James K Karichu, Mindy M Cheng, Maciej B Maniecki
Publicado no BMJ Open (2023-05-01)

Precision Health Economics and Outcomes Research to Support Precision Medicine: Big Data Meets Patient Heterogeneity on the Road to Value

Por Yixi Chen, Gregory F. Guzauskas, Chengming Gu, Bruce C. M. Wang, Wesley E. Furnback, Guotong Xie, Peng Dong, Louis P. Garrison
Publicado no Journal of Personalized Medicine (2016-11-01)

Val (EU) xit: do we need an international ISPOR value flower?

Por Sreeram V Ramagopalan, Manuel Gomes, Isabelle Durand-Zaleski, Bill Malcolm, Jose Diaz, Grace Mitchell, Jonathan Pearson-Stuttard, Louis P Garrison Jr
Publicado no Journal of Comparative Effectiveness Research (2024-07-01)

New Vaccine Platforms—Novel Dimensions of Economic and Societal Value and Their Measurement

Por Philip O. Buck, Dumingu Aparna Gomes, Ekkehard Beck, Noam Kirson, Matthew Mattera, Stuart Carroll, Bernhard Ultsch, Kavisha Jayasundara, Mathieu Uhart, Louis P. Garrison, Jr.
Publicado no Vaccines (2024-02-01)

Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer’s Disease in the United States

Por Malaz Boustani, Erin G. Doty, Louis P. Garrison Jr, Lee J. Smolen, Timothy M. Klein, Daniel R. Murphy, Andrew W. Spargo, Mark Belger, Joseph A. Johnston
Publicado no Neurology and Therapy (2024-09-01)

Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective

Por Phil McEwan, Paolo Antonio Ascierto, Kevin Harrington, Michael B Atkins, Casey Quinn, Louis P Garrison, Anja K Pownell, Gérard de Pouvourville, Samuel Wagner, John Borrill, Elise Wu
Publicado no Journal for ImmunoTherapy of Cancer (2020-10-01)

The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting

Por Howard L. Kaufman, Michael B. Atkins, Adam P. Dicker, Heather S. Jim, Louis P. Garrison, Roy S. Herbst, William T. McGivney, Steven Silverstein, Jon M. Wigginton, Peter P. Yu
Publicado no Journal for ImmunoTherapy of Cancer (2017-04-01)

Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women

Por Horacio A. Duarte, Joseph B. Babigumira, Eva A. Enns, David C. Stauffer, Robert W. Shafer, Ingrid A. Beck, Louis P. Garrison, Jr., Michael H. Chung, Lisa M. Frenkel, Eran Bendavid
Publicado no EClinicalMedicine (2020-05-01)

Estimating the costs of HIV clinic integrated versus non-integrated treatment of pre-cancerous cervical lesions and costs of cervical cancer treatment in Kenya.

Por Elisabeth L Vodicka, Michael H Chung, Marita R Zimmermann, Rose J Kosgei, Fan Lee, Nelly R Mugo, Timothy C Okech, Samah R Sakr, Andy Stergachis, Louis P Garrison, Joseph B Babigumira
Publicado no PLoS ONE (2019-01-01)